I should point out what we all probably know - C14 is pushing BIT225 as an antiviral and not a HIV trreatment.
Sort of indicates a failure by B in the HV field which is disappointing and also limits the scope for C14 to get some ort of commercial partnership underway.
In essence, the antiviral nature of BIT was picked up from trials but there are no specific trials of BIT225 as an antiviral.
BIT Price at posting:
0.3¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)